Background Virulent Bordetella pertussis, the causative agent of whooping cough, exacerbates allergic airway inflammation in a murine model of ovalbumin (OVA) sensitization. A live genetically attenuated B. pertussis mucosal vaccine, BPZE1, has been developed that evokes full protection against virulent challenge in mice but the effect of this attenuated strain on the development of allergic responses is unknown. Objective To assess the influence of attenuated B. pertussis BPZE1 on OVA priming in a murine model of allergic airway inflammation. Methods Mice were challenged with virulent or attenuated strains of B. pertussis, and sensitized to allergen (OVA) at the peak of bacterial carriage. Subsequently, airway pathology, local inflammation and OVA-specific immunity were examined. Results In contrast to virulent B. pertussis, live BPZE1 did not exacerbate but reduced the airway pathology associated with allergen sensitization. BPZE1 immunization before allergen sensitization did not have an adjuvant effect on allergen specific IgE but resulted in a statistically significant decrease in airway inflammation in tissue and bronchoalveolar lavage fluid. BPZE1 significantly reduced the levels of OVA-driven IL-4, IL-5 and IL-13 but induced a significant increase in IFN-g in response to OVA re-stimulation. Conclusions These data demonstrate that, unlike virulent strains, the candidate attenuated B. pertussis vaccine BPZE1 does not exacerbate allergen-driven airway pathology. BPZE1 may represent an attractive T-helper type 1 promoting vaccine candidate for eradication of whooping cough that is unlikely to promote atopic disease.
Introduction
The pathogenesis of allergic asthma remains unclear. However, the current understanding involves the expansion of CD4 1 T-helper type 2 (Th2) cells and a breakdown in tolerance to otherwise innocuous environmental allergens [1] . Genetic predisposition, coupled with environmental influences, appear to affect the regular suppression of Th2-mediated responses [2] . It has been hypothesized that abnormalities in the maturation of the lung during fetal and neonatal development may render the airways more susceptible to environmental allergens [3] , favouring polarization towards the Th2 phenotype and thus, predisposing the individual to atopy and asthma. Allergen-driven production of IL-4, IL-5 and IL-13 are typical of allergic pathologies, and the secretion of such Th2-cytokines initiates isotype class switching of B cells towards IgE [4] , increased mucus production [5] and recruitment of eosinophils to the airways [6, 7] . Because CD4
1 Th2 cells represent a co-ordinating cell type in some allergies, it was suggested that the induction of counterbalancing responses might prevent the subsequent development of atopic disease [1] . According to this modification of Strachan's hygiene hypothesis [8] , microbial exposure activates innate immune pathways that alter Th1, Th2 and Treg responses [1] . This results in the suppression of Th2 cell expansion, and a consequent inhibition of isotype switching to IgE. However, several studies have suggested that viral and bacterial infections play a role in exacerbation of respiratory disease. For example, respiratory syncytial virus [9, 10] and virulent Bordetella pertussis infection exacerbate allergic inflammation [11] . The latter has been shown to exacerbate airway pathology [12, 13] and stimulate IgE responses in a murine model of allergen-driven inflammation despite induction of Th1 immunity [14, 15] . Th2-inducing acellular pertussis (Pa) vaccines protect against B. pertussis-induced exacerbation of allergic asthma, but induce IL-13 both at a systemic and local level [16] . On the other hand, systemic immunization with Th1-inducing whole-cell pertussis (Pw) vaccines inhibits allergic airway responsiveness [17] indicating that protection from allergen-driven pathology is not simply modulation of Th1/Th2 responses, but may also be associated with the degree of airway damage at the time of priming, such that allergen priming in the mucosae during breakdown of the airway epithelial mesenchymal unit may be an equally important factor.
Recently, a genetically attenuated B. pertussis strain, BPZE1, has been developed as a live neonatal mucosal vaccine candidate against whooping cough [18] . This strain induces strong local and systemic immune responses upon a single intranasal delivery [18] . Administration via the nasal route mimics natural infection and is expected to promote long-lasting immunity in children from o1 month of age [19] . Although full attenuation of BPZE1 has been extensively documented in murine models, the influence of BPZE1 administration on allergen priming and allergen-induced pathology is not known, but is of obvious importance in ascertaining the safety of this live vaccine candidate.
This preclinical study compared a virulent pertussis strain, with the candidate vaccine, BPZE1, and examined their effect on the induction of ovalbumin (OVA)-induced airway inflammation using previously characterized animal models. We show here that, unlike virulent strains, attenuated BPZE1 did not exacerbate but reduced allergen-driven pathology.
Materials
Immunization, sensitization and airway delivery of ovalbumin and Bordetella pertussis Eight-to 12-week-old, female BALB/c mice (Harlan, Oxon, UK) were used and maintained according to the regulations and guidelines of the Irish Department of Health, and the Research Ethics Committee of the National University of Ireland, Maynooth. Mice were exposed to live virulent or attenuated bacteria, and sensitized to allergen during infection. Virulent B. pertussis BPSM [20] and attenuated BPZE1 were cultured as previously described [21] . Attenuated or virulent strains at mid-log growth were administered to mice by aerosol using the respiratory challenge model and standard protocols [16] . Briefly mice received set time aerosol exposure which models natural mode of infection to achieve a colonizing dose of 1Â10 6 CFU/mouse. This dose was chosen for three reasons, it was the optimized dose from earlier studies [21] , to be consistent with previous reports in this model [16, 17] and because this standard version of the respiratory challenge protocol had been used in assessment of clinical lots of previous B. pertussis vaccines [13] . At the peak of infection (10 days) and at 24 days, mice were sensitized by intraperitoneal injection (0.3 mL) of 100 mg/mL OVA in adjuvant (AlumImject TM , Pierce, IL, USA). Mice were challenged intranasally (30 mL) with OVA (50 mg/mL) on days 24, 35, 36 and 37. Various control groups (n = 10) received sham delivery of sterile phosphate-buffered saline (PBS) in place of the active agent as previously described [12] .
Bronchoalveolar lavage and respiratory tract histology
On day 37, mice were killed by lethal injection of sodium pentobarbital, and bronchoalveolar lavage fluid (BALF) was collected [12] . Total leucocytes and differential cell counts were performed as described [12] , using Diff Quik/ Rapi-Diff II TM (Triangle Biomedical Sciences, Durham, NC, USA). Lungs from non-lavaged mice were removed and fixed in 10% (v/v) formalin/PBS, embedded in paraffin, sectioned and stained with haematoxylin/eosin, or combined Discombes/Alcian blue and periodic acid-Schiff (PAS) stain [12] . Histopathological changes were graded according to an established semi-quantitative scoring system as mild, moderate or severe [16] , and are shown for convenience in supporting information (Fig. S1 ).
T cell proliferation assay
Splenocytes from mice were prepared as previously described [22] and incubated for 72 h with medium (negative control), OVA (200 mg/mL) or concanavalin A (5 mg/mL). Supernatants were removed after 48-h incubation for cytokine analysis, and cultures received fresh medium. Cells were incubated for the final 6 h with [ 3 H]-thymidine and proliferation was detected by liquid scintillation [23] .
Measurement of cytokines and antibody responses
IL-5, IL-10, IL-13 and IFN-g from BALF and splenocyte supernatants were analysed by flow cytometry (BectonDickinson, Franklin Lakes, NJ, USA), using Cytometric Bead Array Flex Sets (BD Biosciences) according to the manufacturer's instructions. Standard curves and raw data were generated for each cytokine using FCAP Array v1.0.1 software (BD Biosciences). OVA-specific serum IgE was measured by ELISA as previously described [24] using a rat anti-mouse IgE monoclonal antibody (BD Pharmingen, San Diego, CA, USA). IgE concentration was expressed as mg/mL after comparison with murine IgE standards (BD Pharmingen).
Statistical analysis
Values for all measurements were expressed as the mean AE standard error of the mean. Statistical analysis was performed using GraphPad Prism TM software (GraphPad, San Diego, CA, USA). Comparison was made using the Kruskal-Wallis test, or the Mann-Whitney test as appropriate. Significance was denoted by P-value o0.05.
Results
Attenuated Bordetella pertussis BPZE1 prevents ovalbumin-driven allergic airway pathology Virulent B. pertussis can exaggerate unrelated allergen priming in animal models [12] and has been associated with exacerbation of allergy in humans [11] . To assess the influence of the candidate vaccine on OVA-induced airway pathology, mice were challenged with either virulent BPSM, or attenuated BPZE1, and sensitized to OVA at the peak of bacterial carriage (a model previously shown to uncover the influence of infection on allergen-driven inflammation) [12, 13, 16] . In the absence of infection, OVA-sensitized mice exhibited typical peribronchial and perivascular inflammation at day 38, which was not observed in control mice (Figs 1a and b). At this timepoint, pathology due to virulent bacterial infection alone has resolved [22] . Priming at the peak of virulent B. pertussis infection resulted in a more severe pathology when compared with non-infected sensitized mice, displaying strong perivascular inflammation and hypertrophied bronchiolar epithelium (Fig. 1c) . In contrast, prior challenge with attenuated BPZE1 resulted in decreased peribronchial inflammation when compared with sensitized, BPSM-infected mice (Fig. 1d) . Excessive mucus secretion from goblet cells is a characteristic feature of the allergic airway. An examination of lung tissues stained with PAS and Alcian blue demonstrated that prior immunization with BPZE1 in OVA-sensitized mice reduced mucus secretion when compared with those sensitized to OVA alone (Fig. 2) . In contrast, virulent BPSM-infection exacerbated goblet cell hyperplasia and mucus secretion in OVA-sensitized mice (Fig. 2c) . Consistent with these data were physiological observations of airway hyper-responsiveness (AHR) suggesting that prior immunization with BPZE1 resulted in significantly reduced bronchial hyperreactivity compared with mice primed while infected with virulent B. pertussis (supporting information Fig. S2 ). Taken together these data show that unlike infection with virulent B. pertussis, administration of attenuated B. pertussis BPZE1 did not enhance, but reduced the pathology associated with allergen sensitization.
Attenuated Bordetella pertussis BPZE1 prevents ovalbumin-driven allergic airway inflammation
The capacity for live attenuated B. pertussis BPZE1 to influence OVA-induced inflammatory influx to the respiratory tract was examined. OVA sensitization resulted in characteristic inflammation with eosinophils, neutrophils, macrophages and lymphocytes detected in BALF not seen in control mice (Fig. 3) . Mice sensitized during virulent B. pertussis infection showed a similar pattern of inflammation. However, in marked contrast, immunization with live attenuated BPZE1 before OVA sensitization resulted in significantly reduced inflammatory infiltration of the airways (Po0.05) for all cells examined. Thus a major finding of this study was that attenuated B. pertussis BPZE1 reduced OVA-driven allergic airway inflammation typically seen in this model. Bordetella pertussis BPZE1 does not enhance serum immunoglobulin E responses to sensitizing allergen B. pertussis is a known adjuvant for IgE, as is active pertussis toxin [14, 15] . Therefore the influence of BPZE1 on allergic sensitization was examined by measuring the concentration of OVA-specific IgE in serum in these mice. Unlike non-sensitized controls, OVA sensitization induced significant levels of IgE as expected (Fig. 4) . Allergenspecific IgE responses in mice exposed to attenuated BPZE1 before OVA sensitization were not enhanced but were not significantly different to those receiving OVA alone. However, compared with mice infected with virulent BPSM in combination with OVA sensitization, attenuated BPZE1 immunization resulted in a significant reduction (Po0.05) of OVA-induced IgE (Fig. 4) . Therefore, unlike virulent B. pertussis BPSM which damages the airways, live attenuated B. pertussis BPZE1 delivered before allergen priming did not enhance or have an adjuvant effect upon the IgE response to allergen.
Bordetella pertussis BPZE1 modulates recall cytokine responses to sensitizing allergen Attenuated BPZE1 has a radically different effect on allergen-driven airway pathology to virulent B. pertussis. To further investigate this, the influence of bacterial exposure on the pattern of allergen-induced cellular immune responses was characterized. OVA-specific cytokine production in both spleen cell preparations and BALF was assessed in the groups described above, in order to evaluate the influence of BPZE1 on allergen-induced priming. As expected, OVA sensitization alone induced high levels of the Th2 cytokines IL-4, IL-5 and IL-13 (Fig.  5) . Neither virulent BPSM nor attenuated BPZE1 alone induced any recall response to OVA, but both provoked strong Th1 responses to B. pertussis antigens (data not shown), as previously reported [16] . Virulent BPSM challenge before sensitization did not induce a significant reduction in OVA-specific IL-5 or IL-13 and did not increase IFN-g significantly (Fig. 5) . However, a striking increase in IL-4 in BALF was observed when compared with those sensitized to OVA alone. In contrast, BPZE1 modulated the allergen response. Prior BPZE1 significantly reduced the levels of OVA-induced IL-5 (Po0.005), IL-13 (Po0.05) and IL-4 (Po0.005). This was an immunomodulatory effect because suppression was not global; BPZE1 significantly increased IFN-g in BALF and from splenocytes re-stimulated with OVA (Po0.05). In summary, BPZE1 did not promote Th2 cytokine induction to allergen, but rather redirected this to a Th1-like response.
Discussion
The present study combined murine infection and sensitization models to demonstrate that an attenuated strain of B. pertussis, BPZE1, did not enhance but reduced allergen-driven airway pathology. BPZE1 prevented OVA-driven inflammation of the airways, assessed by histological and qualitative analysis of mucus production. Furthermore, BPZE1 diminished the severity of allergendriven inflammation in the lungs. Eosinophilic and neutrophilic infiltration was significantly reduced in BPZE1-immunized mice sensitized to OVA. Virulent BPSM enhanced IL-4 in BALF, whereas BPZE1 modulated allergen responses towards a Th1 phenotype, demonstrated by a marked increase in IFN-g. Likewise, analysis of recall responses to allergen showed that BPZE1 modulated responses away from IL-5 and IL-13 towards IFN-g. In contrast to virulent B. pertussis, BPZE1 demonstrated no adjuvant associated increase in allergen-specific IgE. Taken together, these data demonstrate that attenuated BPZE1 acts as a powerful immunomodulator that suppresses allergen-driven pathology at both a local and systemic level.
Some versions of the hygiene hypothesis suggest that Th1-inducing infections may have an inhibitory effect on the development of atopy [25] . However, previous studies have demonstrated that virulent B. pertussis enhanced the severity of airway pathology [12, 13] despite induction of Th1 immunity. In contrast, systemic immunization with a Th1-inducing Pw vaccine inhibited allergic airway responsiveness [13] . These seemingly counter-intuitive findings suggest that protection from allergen-driven pathology is linked not just to CD4
1 T cell profile, but also to the degree of airway damage at the time of priming [14] . This can be probed using virulent (airway damaging) and attenuated (non-damaging) bacterial strains. The present study supports those findings showing that prior immunization with BPZE1 that does not damage the airway epithelium [26] resulting in significantly reduced allergic pathology, compared with those mice sensitized while infected with virulent B. pertussis that induces airway damage [26] . Vaccination with Pw has been reported to protect against B. pertussis exacerbation of OVA-induced AHR in a murine model of allergic airway inflammation [17] and it has been shown that there is no allergy-promoting effect in response to common childhood vaccines, including pertussis vaccines [27] . However, much less is known about protective effects of childhood vaccines against atopy, others have shown that live attenuated vaccines, such as oral poliomyelitis vaccine or Bacillus-Calmette-Guérin, inhibited the development of asthma and allergic disease [28] . However, the mechanisms underlying the beneficial influence of attenuated BPZE1 on allergen-driven pathology may be multiple and inter-linked. It is known in other models that immune interaction between infection and allergen sensitization critically depends on timing of challenges [29] . In this model, the challenge schedule was chosen to examine the effect of prior immunization on allergen sensitization and for consistency with previous reports [12, 16, 17] . However, it will be important to examine the reverse scenario to assess the effect of immunization on preexisting allergen sensitivity, such as that seen using unmethylated CpG oligodeoxynucleotides which inhibited ragweed allergen induced lung inflammation in presensitized animals [30] .
Pathology in the OVA model is driven by Th2 cytokines, in particular IL-5 and IL-13. However, there are two components to this; the first is the induction of IgE [31, 32] and classical atopic inflammation. The second is Th2-driven fibrosis/remodelling [33] , which can be antagonized by IFN-g [34, 35] . The observations here that allergen-specific IgE was not significantly changed while pathology was reduced in mice immunized with BPZE1 before OVA sensitization (Figs 1 and 4) suggest that a mechanism of protection other than IgE reduction is involved here. The inhibition of allergic airway pathology might be explained by the modulation of the key cytokines involved in remodelling. This study demonstrated that BPZE1 shifted systemic immune responses to OVA away from IL-4, IL-5 and IL-13 towards IFN-g. Both IL-4 and IL-5 contribute to tissue damage and remodelling due to their function as mediators of eosinophil recruitment [36, 37] . Infection with virulent B. pertussis exaggerates the OVA-induced inflammatory influx to the respiratory tract, with an increase in eosinophils (Fig. 3c) , and an associated increase in the severity of airway pathology (Fig. 1e) . Conversely, administration of attenuated BPZE1 before allergen sensitization significantly reduced inflammatory infiltration (Fig. 3) . Airway mucus hypersecretion is in part driven by IL-13 and is a major pathophysiological feature of both allergic asthma [38] and whooping cough [39] . Therefore, it is not surprising that mucus production mirrored IL-13 levels in this study and was significantly reduced in sensitized mice previously exposed to BPZE1 (Fig. 5c) . Taken together, these data suggest that immune modulation in this model has its greatest impact on mucus secretion and remodelling rather than IgE induction. Since attenuation of BPZE1 is based on the genetic removal or attenuation of three major toxins, pertussis toxin, tracheal cytotoxin and dermonecrotic toxin [18] , this study suggests that one, or a combination, of the attenuated virulence factors in BPZE1 plays a role in the adjuvant effect observed with virulent B. pertussis strains. The key finding here is that in contrast to virulent B. pertussis, attenuated BPZE1 did not exacerbate allergen-induced airway pathology in a murine model. BPZE1 has been developed as a new candidate for use as a live, intranasal, single-dose neonatal vaccine against whooping cough [18] . Most current vaccination regimes require three doses, beginning at 2 months of age necessitating 6 months for optimal protection [40] . Therefore, there is a need for vaccines that induce strong protection against B. pertussis in neonates. The data presented here support the use of this candidate vaccine even for populations where exposure to allergens and atopy is prevalent. Allergic airway inflammation is not simply a balance between Th1 and Th2 responses [41] . It might be that the key beneficial feature of BPZE1 is the combination of a Th1 skewed response, combined with the absence of induced airway pathology. This is supported by previous reports in which exacerbation of airway pathology to allergen was associated with allergen priming during a period of airway damage or remodelling [12, 42, 43] . This combined benefit makes BPZE1 an attractive candidate as a neonatal vaccine against whooping cough. Figure S2 . BPZE1 challenge prior to OVA sensitisation decreases airway hyperresponsiveness to sensitising allergen. Airway responsiveness was assessed on day 37 by methacholine induced airflow obstruction from conscious mice using whole-body plethysmography in conjunction with the BioSystem XA software (Buxco Electronics, USA) as previously described [16] . (a) Non-sensitised ( ), OVA-sensitised ( ), BPSM infected1OVA sensitisation ( ) and BPZE1 challenge1OVA sensitisation ( ). (b) Nonsensitised (Control ), OVA-sensitised ( ), non-sensitised BPSM infected ( ) and nonsensitised BPZE1 challenge ( ). Results are expressed as mean enhanced pause (PenH)AES.E.M. Where no error bars are visible, error bars are shorter than the size of the data point symbol. Data points represent the mean PenH from eight mice in this case.
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